ICON Announces Senior Appointments

ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced senior appointments to its clinical research, medical imaging and commercialisation and outcomes services. Dr. Andrew Garrett, Ph.D., has been appointed executive vice president of scientific operations, Dr. Paul McCracken, Ph.D., has joined ICON as vice president of medical imaging, and Jim Carroll has been appointed vice president of real world evidence (RWE).
 
Garrett has more than 30 years of experience within the pharmaceutical and contract research organization (CRO) industries. As ICON’s executive vice president of scientific operations, Garrett has global responsibility for the strategic vision and operational execution of ICON’s scientific operations, including biostatistics and programming, pharmacovigilance, regulatory and medical affairs, medical writing, medical imaging and interactive technologies. Garrett joins ICON from Quintiles, where he led the global clinical analysis and reporting services group, and, prior to that, a number of biostatistics and data management roles. Garrett is a recognised thought leader in data-driven decision making and recently led a structural review of the methodology function of the United Kingdom’s Office for National Statistics to improve its ability to drive innovation and help equip it for the digital economy. Garrett has a bachelor of science degree in economics from the University of Leicester, a masters of science degree in medical statistics from the University of Newcastle, and a Ph.D. in statistics from The Open University in the United Kingdom.
 
McCracken brings to ICON more than 20 years of experience in imaging and pharmaceuticals, with a strong track record of applying imaging and biomarkers to drug discovery and development across a range of therapeutic areas. McCracken joins ICON from Eisai, where he led the Imaging Centre of Excellence, which drives novel approaches for discovery targets and translational biomarkers, primarily through the introduction of imaging genetics and the acceleration of novel PET approaches. Prior to Eisai, McCracken worked at Merck Research Laboratories, where he developed preclinical and translational imaging biomarkers and strategies to assess new molecular and biologic entities. McCracken has a bachelor of science degree in physics from The College of New Jersey, a master of science degree in physics/medical physics from Wright State University and a Ph.D. in biomedical engineering–imaging from the Mayo Clinic College of Medicine.
 
Carroll leads ICON’s Center of Excellence, which develops real world data (RWD) and technology based solutions to support sponsors who are seeking to expand labelling and market access, while staying ahead of the growing demand for evidentiary requirements. Carroll has more than 20 years of CRO and pharmaceutical experience and joins ICON from inVentiv Health, where he led the formation of a new business unit focused on providing novel RWD-driven services. Carroll previously worked at IMS Health (now QuintilesIMS), where he led the development and commercialization of  RWD-based, global analytic solutions to improve decision outcomes across the biopharmaceutical product lifecycle. Carroll has a bachelor of science degree in organic chemistry from the University of Massachusetts at Amherst and a masters of business administration from the Questrom School of Business at Boston University.

“I’m delighted to welcome Andrew, Paul and Jim to the ICON team. They bring a wealth of scientific operational, and commercialisation expertise to ICON which will help us to advance our clients’ products through their development pipelines and also drive their commercial success,” said Dr. Steve Cutler, ICON’s chief operating officer.
 

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development, from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 89 locations in 37 countries and has approximately 12,300 employees.